Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a conventional anti-obesity drug systematically in obese or overweight patients without diabetes.Methods: The randomized controlled trials (RCTs) of semaglutide in obese or overweight patients without diabetes...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_ca6e4c4be99e4aa89cae59c0e81e7c2c | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Xueqin Gao |e author |
| 700 | 1 | 0 | |a Xueqin Gao |e author |
| 700 | 1 | 0 | |a Xiaoli Hua |e author |
| 700 | 1 | 0 | |a Xiaoli Hua |e author |
| 700 | 1 | 0 | |a Xu Wang |e author |
| 700 | 1 | 0 | |a Xu Wang |e author |
| 700 | 1 | 0 | |a Wanbin Xu |e author |
| 700 | 1 | 0 | |a Wanbin Xu |e author |
| 700 | 1 | 0 | |a Yu Zhang |e author |
| 700 | 1 | 0 | |a Yu Zhang |e author |
| 700 | 1 | 0 | |a Chen Shi |e author |
| 700 | 1 | 0 | |a Chen Shi |e author |
| 700 | 1 | 0 | |a Ming Gu |e author |
| 700 | 1 | 0 | |a Ming Gu |e author |
| 245 | 0 | 0 | |a Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials |
| 260 | |b Frontiers Media S.A., |c 2022-09-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2022.935823 | ||
| 520 | |a Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a conventional anti-obesity drug systematically in obese or overweight patients without diabetes.Methods: The randomized controlled trials (RCTs) of semaglutide in obese or overweight patients without diabetes were retrieved from PubMed, Cochrane Library, EMBASE, and ClinicalTrials.gov from database inception until 2 May 2022. Data extraction and quality assessment of studies meeting the inclusion criteria were performed, and statistical analysis was conducted by Review Manager 5.3 and Stata 14.Results: Eight studies involving 4,567 patients were enrolled in the meta-analysis. Compared with placebo, semaglutide induced a significant body weight loss (MD: −10.09%; 95% CI: −11.84 to −8.33; p ˂ 0.00001), elicited a larger reduction in body mass index (MD: −3.71 kg/m2; 95% CI: −4.33 to −3.09; p ˂ 0.00001) and waist circumference (MD: −8.28 cm; 95% CI: −9.51 to −7.04; p ˂ 0.00001), achieved weight loss of more than 5, 10, 15, and 20% with a higher proportion of participants. Semaglutide exhibited a positive effect on blood pressure, C-reactive protein, and lipid profiles, expressed more adverse effects than placebo, mainly gastrointestinal reactions. The results were stable and reliable with dose-dependence.Conclusion: Semaglutide indicated a significant weight loss with an acceptable safety for obese or overweight patients without diabetes. | ||
| 546 | |a EN | ||
| 690 | |a weight loss | ||
| 690 | |a semaglutide | ||
| 690 | |a obesity | ||
| 690 | |a without diabetes | ||
| 690 | |a meta-analysis | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 13 (2022) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fphar.2022.935823/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/ca6e4c4be99e4aa89cae59c0e81e7c2c |z Connect to this object online. |